Veracyte - VCYT Stock Forecast, Price & News

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Veracyte Stock Down 4.1 %

Shares of VCYT Stock traded down $0.93 during trading hours on Friday, reaching $21.89. 26,996 shares of the stock traded hands, compared to its average volume of 893,183. The firm has a market capitalization of $1.57 billion, a PE ratio of -33.56 and a beta of 1.11. The business has a fifty day moving average price of $23.24 and a 200 day moving average price of $23.63. Veracyte has a 1-year low of $14.85 and a 1-year high of $54.13.

Veracyte (NASDAQ:VCYT - Get Rating) last released its quarterly earnings data on Tuesday, August 2nd. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.08. The firm had revenue of $72.86 million for the quarter, compared to analyst estimates of $67.37 million. Veracyte had a negative net margin of 18.13% and a negative return on equity of 4.05%. Research analysts expect that Veracyte will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on VCYT. Needham & Company LLC increased their target price on shares of Veracyte from $26.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Raymond James increased their target price on shares of Veracyte from $30.00 to $31.00 and gave the company an "outperform" rating in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $42.50.

Insider Buying and Selling at Veracyte

In other Veracyte news, Director Jens Holstein sold 8,720 shares of the company's stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $16.27, for a total value of $141,874.40. Following the transaction, the director now owns 2,000 shares in the company, valued at approximately $32,540. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Veracyte news, CEO Marc Stapley bought 60,000 shares of the firm's stock in a transaction on Friday, June 10th. The stock was bought at an average cost of $16.33 per share, with a total value of $979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 159,761 shares of the company's stock, valued at approximately $2,608,897.13. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jens Holstein sold 8,720 shares of the business's stock in a transaction that occurred on Tuesday, June 14th. The stock was sold at an average price of $16.27, for a total transaction of $141,874.40. Following the completion of the sale, the director now directly owns 2,000 shares of the company's stock, valued at $32,540. The disclosure for this sale can be found here. Company insiders own 8.30% of the company's stock.